Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Hoffman

Showing results (151-160 of 204) with videos related to

Pageof 21
Sort By:
Blood|April 27, 2016
A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cellsXiaoli Wang, David Haylock, Cing Siang Hu, et al.
Blood Cells, Molecules & Diseases|March 14, 2007
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasiaVittorio Rosti, Margherita Massa, Alessandro M Vannucchi, et al.
Experimental Hematology|September 5, 2016
Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosisIlaria Ceglia, Amylou C Dueck, Francesca Masiello, et al.
Transfusion|December 6, 2019
Pre-clinical development of a cryopreservable megakaryocytic cell product capable of sustained platelet production in miceAmi Patel, Cara Marie Clementelli, Danuta Jarocha, et al.
Leukemia|February 20, 2026
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy imagesAndrew Srisuwananukorn, Giuseppe Gaetano Loscocco, James M Dolezal, et al.
Leukemia Research|June 3, 2021
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional databaseDouglas Tremblay, Lukas Ronner, Nikolai Podoltsev, et al.
Leukemia Research|June 19, 2022
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center databaseNoa Rippel, Douglas Tremblay, Nicole Zubizarreta, et al.
Blood|October 9, 2004
The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosisMingjiang Xu, Edward Bruno, Joseph Chao, et al.
Leukemia Research|September 4, 2012
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortiumJohn Mascarenhas, Mark L Heaney, Vesna Najfeld, et al.
Leukemia & Lymphoma|June 2, 2024
Impact of gender representativeness in online symptom survey and clinical trial participation among patients with myeloproliferative neoplasmsBlake Langlais, Amylou C Dueck, Heidi E Kosiorek, et al.
Pageof 21

Showing results (151-160 of 204) with videos related to

Sort By:
Pageof 21
Blood|April 27, 2016
A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cellsXiaoli Wang, David Haylock, Cing Siang Hu, et al.
Blood Cells, Molecules & Diseases|March 14, 2007
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasiaVittorio Rosti, Margherita Massa, Alessandro M Vannucchi, et al.
Experimental Hematology|September 5, 2016
Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosisIlaria Ceglia, Amylou C Dueck, Francesca Masiello, et al.
Transfusion|December 6, 2019
Pre-clinical development of a cryopreservable megakaryocytic cell product capable of sustained platelet production in miceAmi Patel, Cara Marie Clementelli, Danuta Jarocha, et al.
Leukemia|February 20, 2026
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy imagesAndrew Srisuwananukorn, Giuseppe Gaetano Loscocco, James M Dolezal, et al.
Leukemia Research|June 3, 2021
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional databaseDouglas Tremblay, Lukas Ronner, Nikolai Podoltsev, et al.
Leukemia Research|June 19, 2022
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center databaseNoa Rippel, Douglas Tremblay, Nicole Zubizarreta, et al.
Blood|October 9, 2004
The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosisMingjiang Xu, Edward Bruno, Joseph Chao, et al.
Leukemia Research|September 4, 2012
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortiumJohn Mascarenhas, Mark L Heaney, Vesna Najfeld, et al.
Leukemia & Lymphoma|June 2, 2024
Impact of gender representativeness in online symptom survey and clinical trial participation among patients with myeloproliferative neoplasmsBlake Langlais, Amylou C Dueck, Heidi E Kosiorek, et al.
Pageof 21